|
|
 Previous Article | Table of Contents | Next Article 
Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene
William P. Fay,
Andrew C. Parker,
Lorraine R. Condrey, and
Amy D. Shapiro
From the Department of Internal Medicine, University of Michigan Medical School, Ann Arbor; and the Department of Pediatrics, Indiana University Medical School, Indianapolis.
Plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of tissue- and urokinase-type plasminogen activators, is considered a critical regulator of the fibrinolytic system. We previously reported a child with abnormal bleeding and complete PAI-1 deficiency caused by a frame-shift mutation in exon 4 of the PAI-1 gene. The purpose of this study was to provide genetic and clinical data on the extended pedigree of the original proband to better define the phenotype associated with PAI-1 deficiency. Allele-specific oligonucleotide hybridization was used to genotype individuals, and serum PAI-1 antigen was measured by enzyme-linked immunosorbent assay. By this approach we have identified 19 individuals who are heterozygous for the PAI-1 null allele and 7 homozygous individuals with complete PAI-1 deficiency. Clinical manifestations of PAI-1 deficiency were restricted to abnormal bleeding, which was observed only after trauma or surgery in homozygous affected individuals. A spectrum of bleeding patterns was observed, including intracranial and joint bleeding after mild trauma, delayed surgical bleeding, severe menstrual bleeding, and frequent bruising. Fibrinolysis inhibitors, including  -aminocaproic acid and tranexamic acid, were effective in treating and preventing bleeding episodes. Other than abnormal bleeding, no significant developmental or other abnormalities were observed in homozygous PAI-1-deficient individuals. Heterozygous PAI-1 deficiency was not associated with abnormal bleeding, even after trauma or surgery. These observations define the clinical spectrum of PAI-1 deficiency and provide additional evidence to support the hypothesis that the primary function of plasminogen activator inhibitor-1 in vivo is to regulate vascular fibrinolysis.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 204-208
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. S. Jacobsen, T. A. Comery, R. L. Martone, H. Elokdah, D. L. Crandall, A. Oganesian, S. Aschmies, Y. Kirksey, C. Gonzales, J. Xu, et al.
Enhanced clearance of A{beta} in brain by sustaining the plasmin proteolysis cascade
PNAS,
June 24, 2008;
105(25):
8754 - 8759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Duggan, M. J. O'Dwyer, E. Caraher, D. Diviney, E. McGovern, D. Kelleher, R. McManus, and T. Ryan
Coagulopathy After Cardiac Surgery May Be Influenced by a Functional Plasminogen Activator Inhibitor Polymorphism
Anesth. Analg.,
June 1, 2007;
104(6):
1343 - 1347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. R. Stoldt, O. Schnorr, K. Schulze-Osthoff, and R. E. Scharf
Transforming growth factor-{beta}1 enhances the antifibrinolytic and prothrombotic state of growing endothelial cells in a cell cycle-specific manner
FASEB J,
May 1, 2006;
20(7):
965 - 966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. M. Hayward
Diagnosis and Management of Mild Bleeding Disorders
Hematology,
January 1, 2005;
2005(1):
423 - 428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Moriwaki, A. Stempien-Otero, M. Kremen, A. E. Cozen, and D. A. Dichek
Overexpression of Urokinase by Macrophages or Deficiency of Plasminogen Activator Inhibitor Type 1 Causes Cardiac Fibrosis in Mice
Circ. Res.,
September 17, 2004;
95(6):
637 - 644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Repine and M. Osswald
Menorrhagia Due to a Qualitative Deficiency of Plasminogen Activator Inhibitor-1: Case Report and Literature Review
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2004;
10(3):
293 - 296.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. T. Askari, M.-L. Brennan, X. Zhou, J. Drinko, A. Morehead, J. D. Thomas, E. J. Topol, S. L. Hazen, and M. S. Penn
Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction
J. Exp. Med.,
March 3, 2003;
197(5):
615 - 624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Chapman Jr. and G.-P. Shi
Protease Injury in the Development of COPD : Thomas A. Neff Lecture
Chest,
May 1, 2000;
117(5_suppl_1):
295S - 299S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Farrehi, C. K. Ozaki, P. Carmeliet, and W. P. Fay
Regulation of Arterial Thrombolysis by Plasminogen Activator Inhibitor-1 in Mice
Circulation,
March 17, 1998;
97(10):
1002 - 1008.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
